224 related articles for article (PubMed ID: 26530261)
1. The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
Ziu M; Kalkanis SN; Gilbert M; Ryken TC; Olson JJ
J Neurooncol; 2015 Dec; 125(3):585-607. PubMed ID: 26530261
[TBL] [Abstract][Full Text] [Related]
2. Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Nahed BV; Redjal N; Brat DJ; Chi AS; Oh K; Batchelor TT; Ryken TC; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):609-30. PubMed ID: 26530264
[TBL] [Abstract][Full Text] [Related]
3. The role of radiotherapy in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Ryken TC; Parney I; Buatti J; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):551-83. PubMed ID: 26530266
[TBL] [Abstract][Full Text] [Related]
4. The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Aghi MK; Nahed BV; Sloan AE; Ryken TC; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):503-30. PubMed ID: 26530265
[TBL] [Abstract][Full Text] [Related]
5. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ
J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344
[TBL] [Abstract][Full Text] [Related]
6. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
[TBL] [Abstract][Full Text] [Related]
7. The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Fouke SJ; Benzinger T; Gibson D; Ryken TC; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):457-79. PubMed ID: 26530262
[TBL] [Abstract][Full Text] [Related]
8. The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Cahill DP; Sloan AE; Nahed BV; Aldape KD; Louis DN; Ryken TC; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):531-49. PubMed ID: 26530263
[TBL] [Abstract][Full Text] [Related]
9. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
10. To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment.
Paľa A; Coburger J; Scherer M; Ahmeti H; Roder C; Gessler F; Jungk C; Scheuerle A; Senft C; Tatagiba M; Synowitz M; Wirtz CR; Schmitz B; Unterberg AW
J Neurosurg; 2019 Jul; ():1-8. PubMed ID: 31323633
[TBL] [Abstract][Full Text] [Related]
11. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Wang J; Yan L; Ai P; He Y; Guan H; Wei Z; He L; Mu X; Liu Y; Peng X
Neurosurg Rev; 2021 Jun; 44(3):1447-1455. PubMed ID: 32529528
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
13. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
Farrell C; Shi W; Bodman A; Olson JJ
J Neurooncol; 2020 Nov; 150(2):269-359. PubMed ID: 33215345
[TBL] [Abstract][Full Text] [Related]
14. Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review.
Hafazalla K; Sahgal A; Jaja B; Perry JR; Das S
Oncotarget; 2018 Sep; 9(72):33623-33633. PubMed ID: 30263090
[TBL] [Abstract][Full Text] [Related]
15. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults.
Redjal N; Nahed BV; Dietrich J; Kalkanis SN; Olson JJ
J Neurooncol; 2020 Nov; 150(2):165-213. PubMed ID: 33215343
[TBL] [Abstract][Full Text] [Related]
16. Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.
Koo T; Lim DH; Seol HJ; Dho YS; Kim IH; Chang JH; Lee J; Jung TY; Gwak HS; Cho KH; Hong CK; Lee IJ; Kim E; Kim JH; Hong YK; Jang HS; Kim CY; Kim IA; Kim SH; Kim YI; Kim EY; Kim WC; Hong S
J Neurooncol; 2018 Nov; 140(2):445-455. PubMed ID: 30097825
[TBL] [Abstract][Full Text] [Related]
17. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
Nitta M; Muragaki Y; Maruyama T; Ikuta S; Komori T; Maebayashi K; Iseki H; Tamura M; Saito T; Okamoto S; Chernov M; Hayashi M; Okada Y
Neurosurg Focus; 2015 Jan; 38(1):E7. PubMed ID: 25599276
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a prognostic gene expression signature for lower-grade glioma following surgery and adjuvant radiotherapy.
Qian DC; Marascio JA; Tobillo R; Lorenz JW; McCall NS; Neill SG; Hoang KB; Olson JJ; Eaton BR; Shu HG; Zhong J
Radiother Oncol; 2022 Oct; 175():93-100. PubMed ID: 35998839
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
[TBL] [Abstract][Full Text] [Related]
20. The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma.
Youland RS; Kreofsky CR; Schomas DA; Brown PD; Buckner JC; Laack NN
J Neurooncol; 2017 Dec; 135(3):535-543. PubMed ID: 28836106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
